makes the selection on the basis of a growth of 57 per cent growth in revenue and 138 per cent in profit for the first half of this year. Considering the drug-maker’s closing price of N6.
09 at the last trading session, the stock is currently priced below its intrinsic value with a PE ratio of 6.66.NEM appears on the strength of its almost one-quarter expansion in sales and an increase of 29 per cent in profit at mid-year. The underwriter sees gross premium written rise to N25.5 billion and bottom-line to N4.1 billion come year end.
Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut: